Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1084) 1084
Publication (56) 56
Newsletter (22) 22
Book Review (19) 19
Book Chapter (6) 6
Government Document (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (878) 878
flecainide (653) 653
male (514) 514
female (506) 506
cardiac & cardiovascular systems (396) 396
anti-arrhythmia agents - therapeutic use (386) 386
middle aged (381) 381
anti-arrhythmia agents - adverse effects (369) 369
flecainide - adverse effects (355) 355
flecainide - therapeutic use (318) 318
aged (317) 317
electrocardiography (301) 301
adult (255) 255
atrial fibrillation - drug therapy (240) 240
index medicus (235) 235
atrial fibrillation (213) 213
anti-arrhythmia agents - administration & dosage (163) 163
flecainide - administration & dosage (163) 163
arrhythmias, cardiac - drug therapy (151) 151
treatment outcome (140) 140
pharmacology & pharmacy (139) 139
animals (125) 125
sinus rhythm (124) 124
drug therapy (115) 115
arrhythmia (110) 110
amiodarone (106) 106
efficacy (104) 104
time factors (102) 102
cardiac arrhythmia (99) 99
follow-up studies (98) 98
tachycardia, supraventricular - drug therapy (98) 98
arrhythmias (97) 97
encainide (97) 97
tachycardia (96) 96
arrhythmias, cardiac - chemically induced (93) 93
therapy (93) 93
administration, oral (92) 92
propafenone (92) 92
antiarrhythmic drugs (87) 87
supraventricular tachycardia (87) 87
management (84) 84
heart rate - drug effects (80) 80
atrial fibrillation - physiopathology (79) 79
amiodarone - therapeutic use (78) 78
anti-arrhythmia agents - pharmacology (76) 76
dose-response relationship, drug (76) 76
anti-arrhythmia drugs (74) 74
flutter (74) 74
heart conduction system - drug effects (74) 74
flecainide acetate (73) 73
medicine, general & internal (72) 72
piperidines - adverse effects (72) 72
tachycardia - drug therapy (71) 71
electrocardiography - drug effects (69) 69
adolescent (68) 68
retrospective studies (68) 68
electrophysiology (64) 64
quinidine (64) 64
risk factors (64) 64
flecainide - pharmacology (62) 62
cardioversion (61) 61
aged, 80 and over (60) 60
piperidines - therapeutic use (60) 60
drug therapy, combination (59) 59
heart (59) 59
mortality (59) 59
electric countershock (58) 58
arrhythmias, cardiac - physiopathology (57) 57
infusions, intravenous (57) 57
prospective studies (55) 55
safety (55) 55
propafenone - therapeutic use (54) 54
atrial fibrillation - therapy (53) 53
care and treatment (53) 53
digoxin (53) 53
cardiac pacing, artificial (52) 52
double-blind method (52) 52
clinical trials as topic (51) 51
drugs (50) 50
atrial flutter - drug therapy (49) 49
cardiology (49) 49
fibrillation (49) 49
medicine & public health (49) 49
pregnancy (49) 49
cardiovascular (47) 47
conversion (47) 47
analysis (46) 46
propafenone - adverse effects (46) 46
amiodarone - adverse effects (45) 45
anilides - adverse effects (45) 45
recurrence (44) 44
anilides - therapeutic use (43) 43
proarrhythmia (43) 43
sotalol (43) 43
cardiovascular system (42) 42
electrical cardioversion (42) 42
heart conduction system - physiopathology (42) 42
atrial flutter (41) 41
evaluation (40) 40
flecainide - blood (40) 40
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1034) 1034
French (26) 26
German (21) 21
Italian (9) 9
Spanish (7) 7
Japanese (5) 5
Chinese (3) 3
Norwegian (2) 2
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment
by Alboni, Paolo and Botto, Giovanni L and Boriani, Giuseppe and Russo, Giovanni and Pacchioni, Federico and Iori, Matteo and Pasanisi, Giovanni and Mancini, Marina and Mariconti, Barbara and Capucci, Alessandro
Heart, ISSN 1355-6037, 04/2010, Volume 96, Issue 7, pp. 546 - 549
BackgroundPill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe... 
TRIAL | HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | SINGLE | EFFICACY | CONVERSION | DOUBLE-BLIND | CARDIOVERSION | ORAL PROPAFENONE | SINUS RHYTHM | Tablets | Administration, Oral | Atrial Fibrillation - drug therapy | Flecainide - administration & dosage | Humans | Middle Aged | Propafenone - adverse effects | Hospitalization | Anti-Arrhythmia Agents - administration & dosage | Ambulatory Care | Flecainide - adverse effects | Young Adult | Self Administration | Anti-Arrhythmia Agents - adverse effects | Adolescent | Adult | Propafenone - administration & dosage | Aged | Infusions, Intravenous | Drug Therapy, Combination | Complications and side effects | Atrial fibrillation | Dosage and administration | Research | Flecainide | Propafenone | Drug therapy | Studies | Heart rate | Cardiac arrhythmia | Heart attacks | Hospitals | Cognition & reasoning | Electrocardiography | Cardiovascular disease | Blood pressure | Family medical history | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Selective Inhibition of the Late Sodium Current has No Adverse Effect on Electrophysiological or Contractile Function of the Normal Heart
by Fernandes, Sarah and Hoyer, Kirsten and Liu, Gongxin and Wang, Wei-Qun and Dhalla, Arvinder K and Belardinelli, Luiz and Rajamani, Sridharan
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 06/2014, Volume 63, Issue 6, pp. 512 - 519
Inhibition of cardiac late Na current (INa,L) decreases sodium-dependent calcium overload in diseased hearts. Because INa,L is small in the absence of disease,... 
GS967 | Sodium channel | Flecainide | Ivabradine | ARRHYTHMIAS | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCYTES | EFFICACY | BRADYCARDIAC AGENT | ANTIANGINAL AGENT | flecainide | ACUTE CORONARY SYNDROMES | PATHOPHYSIOLOGY | late I-Na | ivabradine | sodium channel | RANOLAZINE | PHARMACOLOGY & PHARMACY | CHANNELS | Rabbits | Heart - physiology | Myocardial Contraction - physiology | Electrophysiological Phenomena - physiology | Myocardial Contraction - drug effects | Rats | Male | Sodium Channel Blockers - pharmacology | Rats, Sprague-Dawley | Triazoles - pharmacology | Heart Rate - drug effects | Animals | Heart - drug effects | Heart Rate - physiology | Female | Pyridines - pharmacology | Organ Culture Techniques | Electrophysiological Phenomena - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Induced brugada-type electrocardiogram, a sign for imminent malignant arrhythmias
by Junttila, M Juhani and Gonzalez, Maday and Lizotte, Eric and Benito, Begona and Vernooy, Kevin and Sarkozy, Andrea and Huikuri, Heikki V and Brugada, Pedro and Brugada, Josep and Brugada, Ramon
Circulation, ISSN 0009-7322, 04/2008, Volume 117, Issue 14, pp. 1890 - 1893
SUDDEN CARDIAC DEATH | PERIPHERAL VASCULAR DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | HEMATOLOGY | ST SEGMENT ELEVATION | Brugada Syndrome - genetics | Brugada Syndrome - diagnosis | Fever - complications | Humans | Middle Aged | Male | Muscle Proteins - deficiency | Brugada Syndrome - complications | Death, Sudden, Cardiac - etiology | Sodium Channel Blockers - adverse effects | Fatal Outcome | Adult | Female | Water-Electrolyte Imbalance - complications | Cocaine - adverse effects | NAV1.5 Voltage-Gated Sodium Channel | Sodium Channels - deficiency | Electrocardiography - drug effects | Brugada Syndrome - chemically induced | Procainamide - adverse effects | Flecainide - adverse effects | Muscle Proteins - genetics | Age of Onset | Antidepressive Agents, Tricyclic - adverse effects | Heart Arrest - etiology | Methadone - adverse effects | Sodium Channels - genetics | Brugada Syndrome - etiology | Anesthetics - adverse effects | Propofol - adverse effects | Electrocardiography | Diagnosis | Arrhythmia | Electrocardiogram | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation
by Cosedis Nielsen, Jens and Johannessen, Arne and Raatikainen, Pekka and Hindricks, Gerhard and Walfridsson, Håkan and Kongstad, Ole and Pehrson, Steen and Englund, Anders and Hartikainen, Juha and Mortensen, Leif Spange and Hansen, Peter Steen and Kardiologi and Cardiology and Lund University and Lunds universitet
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 17, pp. 1587 - 1595
In this trial, patients with symptomatic paroxysmal atrial fibrillation were assigned to either radiofrequency ablation or antiarrhythmic drug therapy as... 
TRIAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EFFICACY | SUBSTRATE | PULMONARY VEIN ABLATION | GUIDELINES | CATHETER ABLATION | COMPLICATIONS | SOCIETY | ANTIARRHYTHMIC-DRUG THERAPY | Follow-Up Studies | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Propafenone - adverse effects | Cost of Illness | Male | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Atrial Fibrillation - surgery | Flecainide - adverse effects | Anti-Arrhythmia Agents - adverse effects | Atrial Flutter - diagnosis | Intention to Treat Analysis | Statistics, Nonparametric | Quality of Life | Female | Aged | Propafenone - therapeutic use | Catheter Ablation - adverse effects | Atrial Fibrillation - diagnosis | Electrocardiography, Ambulatory | Flecainide - therapeutic use | Care and treatment | Usage | Atrial fibrillation | Patient outcomes | Anti-arrhythmia drugs | Radiofrequency ablation | Dosage and administration | Drug therapy | Heart | Fees & charges | Cardiac arrhythmia | Stroke | Arrhythmia | Platelet-activating factor | Cardiovascular disease | Grants | Patients | Catheters | Manuscripts | Tamponade | Fibrillation | Motivation | Electrocardiography | Drug dosages | Antiarrhythmic agents | Veins & arteries | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management
by Gillis, Anne M., MD, FRCPC and Verma, Atul, MD, FRCPC and Talajic, Mario, MD, FRCPC and Nattel, Stanley, MD, FRCPC and Dorian, Paul, MD, FRCPC and CCS Atrial Fibrillation Guidelines and CCS Atrial Fibrillation Guidelines Committee
Canadian Journal of Cardiology, ISSN 0828-282X, 2011, Volume 27, Issue 1, pp. 47 - 59
Abstract The goals of atrial fibrillation (AF) and atrial flutter (AFL) arrhythmia management are to alleviate patient symptoms, improve patient quality of... 
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | INTRAVENOUS AMIODARONE | RENIN-ANGIOTENSIN SYSTEM | TORSADE-DE-POINTES | POLYUNSATURATED FATTY-ACIDS | FOLLOW-UP | ANTIARRHYTHMIC THERAPY | CONGESTIVE-HEART-FAILURE | VENTRICULAR RATE CONTROL | SINUS RHYTHM | ELECTRICAL CARDIOVERSION | Digoxin - adverse effects | Calcium Channel Blockers - adverse effects | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Catheter Ablation | Pacemaker, Artificial | Sotalol - therapeutic use | Dose-Response Relationship, Drug | Amiodarone - adverse effects | Heart Rate - drug effects | Sotalol - adverse effects | Amiodarone - therapeutic use | Adrenergic beta-Antagonists - adverse effects | Adult | Cardiac Output, Low - drug therapy | Drug Therapy, Combination | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Propafenone - adverse effects | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Cardiac Output, Low - complications | Amiodarone - analogs & derivatives | Flecainide - adverse effects | Canada | Myocardial Infarction - complications | Algorithms | Myocardial Infarction - drug therapy | Anti-Arrhythmia Agents - adverse effects | Atrial Fibrillation - etiology | Atrial Flutter - drug therapy | Aged | Propafenone - therapeutic use | Referral and Consultation | Flecainide - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration
by Marum, Alexandre A and Silva, Anderson C and Silva, Bruna A and Bortolotto, Alexandre L and de Antonio, Victor Z and Belardinelli, Luiz and Verrier, Richard L
International Journal of Cardiology, ISSN 0167-5273, 01/2019, Volume 274, pp. 170 - 174
We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial... 
Flecainide | Pharmacologic conversion | Atrial fibrillation | Pulmonary delivery | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | Dosage and administration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation
by Freemantle, Nick and Lafuente-Lafuente, Carmelo and Mitchell, Stephen and Eckert, Laurent and Reynolds, Matthew
Europace, ISSN 1099-5129, 03/2011, Volume 13, Issue 3, pp. 329 - 345
Aims Mixed treatment comparisons (MTC) were performed to assess the relative efficacy and tolerability of the main antiarrhythmic drugs used for the treatment... 
LONG-TERM MAINTENANCE | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | HEART-FAILURE | LOW-DOSE AMIODARONE | DOUBLE-BLIND | RANDOMIZED-TRIAL | PLACEBO-CONTROLLED TRIAL | NORMAL SINUS RHYTHM | SUSTAINED-RELEASE | ELECTRICAL CARDIOVERSION | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Propafenone - adverse effects | Male | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Sotalol - therapeutic use | Amiodarone - analogs & derivatives | Randomized Controlled Trials as Topic | Flecainide - adverse effects | Amiodarone - adverse effects | Sotalol - adverse effects | Amiodarone - therapeutic use | Anti-Arrhythmia Agents - adverse effects | Female | Aged | Propafenone - therapeutic use | Flecainide - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation
by Camm, A. John, MD and Capucci, Alessandro, MD and Hohnloser, Stefan H., MD and Torp-Pedersen, Christian, MD and Van Gelder, Isabelle C., MD and Mangal, Brian, MSc and Beatch, Gregory, PhD and Avro Investigators and AVRO Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2011, Volume 57, Issue 3, pp. 313 - 321
Objectives This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of... 
Cardiovascular | Internal Medicine | atrial fibrillation | amiodarone | antiarrhythmics | vernakalant | cardioversion | CONTROLLED-TRIAL | FLUTTER | PROPAFENONE | IBUTILIDE | UMCG Approved | RAPID CONVERSION | EMERGENCY-DEPARTMENT | INTRAVENOUS PROCAINAMIDE | SINUS RHYTHM | ANTIARRHYTHMIC AGENT | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | FLECAINIDE | Anisoles - adverse effects | Acute Disease | Double-Blind Method | Follow-Up Studies | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Pyrrolidines - adverse effects | Male | Treatment Outcome | Atrial Fibrillation - physiopathology | Pyrrolidines - therapeutic use | Amiodarone - adverse effects | Amiodarone - therapeutic use | Female | Aged | Anisoles - therapeutic use | Continuing medical education | Amiodarone | Cardiology | Atrial fibrillation | Heart failure | Cardiac arrhythmia | Heart attacks | Sinuses | Cardiomyopathy | Cardiovascular disease | Blood pressure | Family medical history | Drug therapy | Acute coronary syndromes | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics
by Wu, Chuntao and Tcherny-Lessenot, Stephanie and Dai, Wanju and Wang, Yunxun and Kechemir, Hayet and Gandhi, Sampada and Lin, Stephen and Juhaeri, Juhaeri
Clinical Therapeutics, ISSN 0149-2918, 03/2018, Volume 40, Issue 3, pp. 450 - 455.e1
There are few data on the risk for peripheral neuropathy associated with dronedarone, a newer antiarrhythmic medicine. The objective of this study was to... 
flecainide | amiodarone | propafenone | peripheral neuropathy | sotalol | dronedarone | AMIODARONE THERAPY | PHARMACOLOGY & PHARMACY | NEUROTOXICITY | Peripheral Nervous System Diseases - chemically induced | Dronedarone - adverse effects | Atrial Fibrillation - drug therapy | Flecainide - administration & dosage | Humans | Middle Aged | Propafenone - adverse effects | Male | Anti-Arrhythmia Agents - therapeutic use | Flecainide - adverse effects | Sotalol - administration & dosage | Amiodarone - adverse effects | Sotalol - adverse effects | Amiodarone - therapeutic use | Dronedarone - administration & dosage | Anti-Arrhythmia Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Propafenone - therapeutic use | Retrospective Studies | Cohort Studies | Databases, Factual | Heart failure | Cardiac arrhythmia | Neurotoxicity | Heart attacks | Peripheral neuropathy | Drug therapy | Patients | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy
by Ermakov, Simon, MD and Gerstenfeld, Edward P., MD, FHRS and Svetlichnaya, Yana, MD, MSc and Scheinman, Melvin M., MD, FHRS
Heart Rhythm, ISSN 1547-5271, 2016, Volume 14, Issue 4, pp. 564 - 569
Background Antiarrhythmic therapy is commonly used for suppression of arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) in... 
Cardiovascular | Ventricular arrhythmia | Arrhythmogenic right ventricular cardiomyopathy | Combination therapy | Antiarrhythmic therapy | Clinical electrophysiology | ARRHYTHMIAS | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | TACHYCARDIA | DYSPLASIA | DRUGS | CATHETER ABLATION | DYSPLASIA/CARDIOMYOPATHY | Recurrence | Flecainide - administration & dosage | Humans | Middle Aged | Male | Drug Monitoring - methods | Arrhythmogenic Right Ventricular Dysplasia - diagnosis | Arrhythmogenic Right Ventricular Dysplasia - physiopathology | Sotalol - adverse effects | Adult | Female | Catheter Ablation - adverse effects | Treatment Outcome | Metoprolol - administration & dosage | Metoprolol - adverse effects | Anti-Arrhythmia Agents - administration & dosage | Arrhythmogenic Right Ventricular Dysplasia - therapy | Catheter Ablation - methods | Flecainide - adverse effects | Sotalol - administration & dosage | Drug Therapy, Combination - methods | Anti-Arrhythmia Agents - adverse effects | Drug Monitoring - statistics & numerical data | Combined Modality Therapy - methods | Electrophysiologic Techniques, Cardiac - methods | Care and treatment | Usage | Arrhythmia | Cardiomyopathy | Cardiac patients | Flecainide | Heart diseases | Ablation (Surgery) | Gene mutations | Implants, Artificial | Prosthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes From an International Multicenter Registry
by Roston, Thomas M and Vinocur, Jeffrey M and Maginot, Kathleen R and Mohammed, Saira and Salerno, Jack C and Etheridge, Susan P and Cohen, Mitchell and Hamilton, Robert M and Pflaumer, Andreas and Kanter, Ronald J and Potts, James E and LaPage, Martin J and Collins, Kathryn K and Gebauer, Roman A and Temple, Joel D and Batra, Anjan S and Erickson, Christopher and Miszczak-Knecht, Maria and Kubuš, Peter and Bar-Cohen, Yaniv and Kantoch, Michal and Thomas, Vincent C and Hessling, Gabriele and Anderson, Chris and Young, Ming-Lon and Cabrera Ortega, Michel and Lau, Yung R and Johnsrude, Christopher L and Fournier, Anne and Kannankeril, Prince J and Sanatani, Shubhayan
Circulation: Arrhythmia and Electrophysiology, ISSN 1941-3149, 06/2015, Volume 8, Issue 3, pp. 633 - 642
BACKGROUND—Catecholaminergic polymorphic ventricular tachycardia is an uncommon, potentially lethal, ion channelopathy. Standard therapies have high failure... 
implanted cardioverter defibrillator | flecainide | polymorphic catecholaminergic ventricular tachycardia | sudden unexpected death | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | SUDDEN-DEATH | SYMPATHECTOMY | FOLLOW-UP | DENERVATION | DEFIBRILLATOR | FLECAINIDE THERAPY | MICE | MUTATIONS | EXERCISE-INDUCED ARRHYTHMIAS | Sympathectomy - mortality | Age Factors | Humans | Death, Sudden, Cardiac - prevention & control | Male | Death, Sudden, Cardiac - etiology | Electric Countershock - adverse effects | Patient Selection | Time Factors | Defibrillators, Implantable | Sympathectomy - adverse effects | Female | Registries | Retrospective Studies | Child | Severity of Illness Index | Tachycardia, Ventricular - therapy | Tachycardia, Ventricular - complications | Risk Factors | Electric Countershock - mortality | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Phenotype | Tachycardia, Ventricular - physiopathology | Tachycardia, Ventricular - mortality | Electric Countershock - instrumentation | Anti-Arrhythmia Agents - adverse effects | Tachycardia, Ventricular - diagnosis | Adolescent | left cardiac sympathetic denervation | catecholaminergic polymorphic ventricular tachycardia | CPVT
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia
by Watanabe, Hiroshi, MD, PhD, FESC and van der Werf, Christian, MD and Roses-Noguer, Ferran, MD and Adler, Arnon, MD and Sumitomo, Naokata, MD and Veltmann, Christian, MD and Rosso, Raphael, MD and Bhuiyan, Zahurul A., MD, PhD and Bikker, Hennie, PhD and Kannankeril, Prince J., MD, MSCI and Horie, Minoru, MD, PhD and Minamino, Tohru, MD, PhD and Viskin, Sami, MD and Knollmann, Björn C., MD, PhD and Till, Jan, MD and Wilde, Arthur A.M., MD, PhD
Heart Rhythm, ISSN 1547-5271, 2013, Volume 10, Issue 4, pp. 542 - 547
Background Conventional therapy with beta-blockers is incompletely effective in preventing arrhythmic events in patients with catecholaminergic polymorphic... 
Cardiovascular | Antiarrhythmic drugs | Arrhythmia | Sudden death | Catecholaminergic polymorphic ventricular tachycardia | Genotype | Beta-blockers | Flecainide | CARDIAC & CARDIOVASCULAR SYSTEMS | SUDDEN-DEATH | CA2+ RELEASE | PHENOTYPE | THERAPY | CHANNEL | CASQ2 | MICE | MUTATIONS | Prospective Studies | Follow-Up Studies | Humans | Male | Young Adult | Electrocardiography | Tachycardia, Ventricular - genetics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Child | Adrenergic beta-Antagonists - therapeutic use | Risk Assessment | Tachycardia, Ventricular - drug therapy | Tachycardia, Ventricular - etiology | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Flecainide - adverse effects | Exercise Test - adverse effects | Tachycardia, Ventricular - physiopathology | Tachycardia, Ventricular - mortality | Anti-Arrhythmia Agents - adverse effects | Tachycardia, Ventricular - diagnosis | Adolescent | Survival Analysis | Cohort Studies | Flecainide - therapeutic use | Heart failure | Sects | Medical colleges | Implants, Artificial | Prosthesis | Analysis | Ventricular tachycardia | Genetic aspects | sudden death | catecholaminergic polymorphic ventricular tachycardia | genetics | arrhythmia | beta-blockers | antiarrhythmic drugs | flecainide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade
by Padfield, Gareth J., MBChB, PhD and AlAhmari, Leenah and Lieve, Krystien V.V., MD and AlAhmari, Tasneem and Roston, Thomas M., MD and Wilde, Arthur A., MD, PhD, FHRS and Krahn, Andrew D., MD, FHRS and Sanatani, Shubhayan, MD, FHRS
Heart Rhythm, ISSN 1547-5271, 2016, Volume 13, Issue 2, pp. 609 - 613
Cardiovascular | Catecholaminergic polymorphic ventricular tachycardia | Side effects | β-blockers | Treatment | Arrhythmia | Flecainide | Catecholaminergic polymorphic ventricular tachy-cardia | ARRHYTHMIAS | CARDIAC & CARDIOVASCULAR SYSTEMS | CA2+ SPARK | beta-blockers | CHILDREN | Flecainide - administration & dosage | Tachycardia, Ventricular - drug therapy | Humans | Drug Tolerance | Medication Therapy Management | Treatment Outcome | Voltage-Gated Sodium Channel Blockers - administration & dosage | Drug Substitution - methods | Anti-Arrhythmia Agents - administration & dosage | Patient Selection | Dose-Response Relationship, Drug | Flecainide - adverse effects | Tachycardia, Ventricular - physiopathology | Anti-Arrhythmia Agents - adverse effects | Tachycardia, Ventricular - diagnosis | Adrenergic beta-Antagonists - adverse effects | Adult | Drug Monitoring | Voltage-Gated Sodium Channel Blockers - adverse effects | Adrenergic beta-Antagonists - administration & dosage | Electrocardiography - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach
by Alboni, Paolo and Botto, Giovanni L and Baldi, Nicola and Luzi, Mario and Russo, Vitantonio and Gianfranchi, Lorella and Marchi, Paola and Calzolari, Massimo and Solano, Alberto and Baroffio, Raffaele and Gaggioli, Germano
New England Journal of Medicine, ISSN 0028-4793, 12/2004, Volume 351, Issue 23, pp. 2384 - 2391
In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating... 
Heart Failure - complications | Prospective Studies | Follow-Up Studies | Administration, Oral | Atrial Fibrillation - drug therapy | Flecainide - administration & dosage | Humans | Middle Aged | Propafenone - adverse effects | Atrial Fibrillation - complications | Heart Failure - physiopathology | Male | Anti-Arrhythmia Agents - therapeutic use | Anti-Arrhythmia Agents - administration & dosage | Ambulatory Care | Feasibility Studies | Flecainide - adverse effects | Stroke Volume | Self Administration | Anti-Arrhythmia Agents - adverse effects | Female | Propafenone - administration & dosage | Propafenone - therapeutic use | Flecainide - therapeutic use | Atrial fibrillation | Ambulatory medical care | Research | Heart rate | Studies | Cardiac arrhythmia | Cardiovascular disease | Emergency medical care | Hospitalization | Drug dosages | Catheters
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights